Lifestyle Intervention Slows Biological Aging in Frail Older Adults
Aging has traditionally been regarded as a unidirectional biological process driven by time and genetics. However, contemporary research in biogerontology increasingly challenges this view, suggesting that certain hallmarks of aging may be modifiable. A recent randomized controlled trial published in Aging Cell (1). provides new evidence that lifestyle interventions may influence both functional decline and molecular indicators of biological aging in frail older adults. The findings offer important insights into how behavioral factors may shape aging trajectories, even in advanced age.
The six-month intervention, conducted by researchers at the University of Valencia in Spain, produced striking improvements across multiple measures of health. Participants who received the multidomain treatment showed reduced frailty scores, better physical function, and remarkably, favorable changes in epigenetic markers of aging compared to those receiving standard care.
Frailty: A State of Biological Vulnerability
Frailty is not simply a consequence of growing older. Frailty is a multidimensional clinical syndrome characterized by reduced physiological reserves and diminished resilience to stressors. Rather than representing a single disease, frailty reflects cumulative dysregulation across multiple systems, including musculoskeletal, metabolic, neurological, and immune pathways. Clinically, frail individuals exhibit weakness, slowed mobility, fatigue, and heightened vulnerability to adverse outcomes such as falls, hospitalization, disability, and mortality (2, 3).
Biologically, frailty reflects cumulative dysregulation across multiple systems. Musculoskeletal weakness, impaired energy metabolism, inflammatory imbalance, and neurophysiological decline often converge, producing a state in which even minor stressors can trigger disproportionate health deterioration (4).
Biological Age vs. Chronological Age
Chronological age poorly reflects physiological heterogeneity, as individuals of the same age often differ markedly in functional capacity and disease risk (5). Biological age biomarkers aim to capture this variability, with epigenetic clocks (6, 7) and telomere length (8). among the most widely studied.
DNA methylation, a regulatory modification at CpG sites, links environmental exposures and cellular function without altering DNA sequence (9). Predictable age-related methylation patterns enabled the development of epigenetic clocks. First-generation clocks estimate chronological age, while second-generation models such as DNAm PhenoAge and DNAm GrimAge better reflect morbidity and mortality risk (10, 11). Newer clocks, including DNAm FitAge, attempt to capture functional resilience (12).
Telomere length represents a complementary marker of genomic stability, with shortening associated with aging and disease (13). Together, these measures provide distinct yet overlapping views of aging biology. Epigenetic age acceleration and the Rate of Epigenetic Aging (REA) quantify deviations from expected aging trajectories and have been linked to adverse outcomes (14).
Importantly, epigenetic clocks demonstrate sensitivity to interventions, suggesting that biological aging processes may be modifiable. Their application to frailty research offers a framework for connecting lifestyle, molecular regulation, and functional decline.
A Multidomain Lifestyle Intervention
In the Aging Cell trial, researchers tested whether a six-month multidomain lifestyle intervention could modify functional and molecular outcomes in frail, community-dwelling older adults. Participants were randomized to either an intervention or habitual-care control group.
The intervention combined protein-rich nutritional supplementation with supervised multicomponent exercise, including resistance, aerobic, and balance training. Functional improvements were striking. Frailty scores declined significantly, accompanied by increased grip strength, faster gait speed, and better balance. Healthcare utilization also decreased, reflected by fewer primary care visits.
Participants exhibited favorable body composition changes, with increased lean mass and reduced fat percentage and abdominal girth. Biochemical markers supported these findings, showing elevated calcidiol, total proteins, calcium, and folic acid, alongside reduced urea levels, consistent with improved nutritional and metabolic status.
Molecular Aging Signals: Epigenetic Clocks and Rate of Epigenetic Aging (REA)
A subset of participants underwent whole-blood DNA methylation analysis to assess epigenetic aging dynamics. While first-generation clocks showed minimal change, DNAm PhenoAge revealed a statistically significant divergence between groups. Control subjects exhibited increases in biological age estimates, whereas intervention participants demonstrated slight decreases.
Parallel analyses of DNA methylation-based telomere length estimators suggested telomere shortening in controls but preservation in the intervention group (Fig. 1). Although modest, these findings suggest that lifestyle factors may influence molecular processes associated with biological aging (15, 16).
The molecular findings may be the study’s most intriguing contribution. The researchers analyzed five different “epigenetic clocks”, DNA methylation patterns that estimate biological age, and found that one in particular, called DNAm PhenoAge, showed significant differences between groups.
While the control group’s biological age increased by approximately 4.1 years over the six-month period (accelerating faster than chronological time), the intervention group actually showed a slight decrease of 0.9 years. This difference was statistically significant and suggests the intervention was influencing aging processes at the cellular level.
The study also found that telomere length, protective caps on chromosomes that typically shorten with age, was preserved in the intervention group but declined in controls. Telomere shortening is a well-established hallmark of aging and cellular deterioration.
To quantify the dynamics of aging, researchers calculated a “Rate of Epigenetic Aging” (REA). An REA greater than 1 indicates biological aging is outpacing chronological aging, while values below 1 suggest the opposite. The control group’s mean REA was 8.4, indicating rapid biological aging, while the intervention group showed a negative value of -1.7, suggesting biological rejuvenation.
Scientific Perspective and Limitations
While the findings are promising, several limitations warrant caution. Molecular analyses were constrained by sample size, DNA methylation was measured only in blood, and the combined intervention design precludes separation of exercise and nutritional effects. Additionally, the study duration limits inference regarding long-term sustainability.
Thus, the results should be interpreted as evidence of modifiable aging-associated biomarkers rather than definitive proof of aging reversal.
Implications for Healthy Aging
These findings reinforce growing evidence that lifestyle interventions can influence core aging mechanisms. While prior multidomain trials such as FINGER and SPRINTT demonstrated clinical benefits, this study uniquely integrates molecular aging biomarkers with functional outcomes in frail older adults.
The results highlight DNAm PhenoAge and telomere length as potential tools for monitoring intervention effects and individual variability in response. Such biomarkers may support more precise evaluation of strategies aimed at improving health span.
Importantly, the study underscores that frailty is not an inevitable consequence of aging. Even in vulnerable older individuals, targeted combinations of nutrition and exercise may improve functional capacity while favorably modifying biological aging signals. The remaining challenge is the development of scalable, accessible interventions capable of delivering these benefits at the population level.
Image credit: Portions of the figure in this article were generated using ChatGPT (OpenAI) or Google Gemini.
Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.
About Marin Biologic Laboratories
Our Recent Publication/Meeting Presentation on Gene Therapy
1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.
3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.
3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.
Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise
With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.
Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.
Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories
Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)
Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)
- ADME/Tox
- Molecular Biology
- The Art of Cell Culture
- Exosomes
- Stability Services
- Potency Assay
- Gene Therapy Assays
- Immunotherapy Assays
- Antiviral Therapy Assays
- cGMP
- MLR
- Cell Based Assays
- ELISA
- Flow Cytometry
- Protein
- PCR-qPCR
- Immunoassay
- Radioimmunoassay
- GLP
- Transfection
- Cell Therapy Assays
- Targeted Protein Degradation
- Research to Commercialization
